Article
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
American journal of epidemiology - 15 Jan 2017
Ahern Thomas P, Hertz Daniel L, Damkier Per, Ejlertsen Bent, Hamilton-Dutoit Stephen J, Rae James M, Regan Meredith M, Thompson Alastair M, Lash Timothy L, Cronin-Fenton Deirdre P
Abstract excerpt
Tamoxifen therapy for estrogen receptor-positive breast cancer reduces the risk of recurrence by approximately one-half. Cytochrome P-450 2D6, encoded by the polymorphic cytochrome P-450 2D6 gene (CYP2D6), oxidizes tamoxifen to its most active metabolites. Steady-state concentrations of endoxifen (4-hydroxy-N-desmethyltamoxifen), the most potent antiestrogenic metabolite, are reduced in women whose CYP2D6...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.